Bringing hope to each patient
is our strongest driver

Services

Notable Studies

cells up close, About page
EAE120
Multiple Myeloma

A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, lenalidomide and dexamethasone in patients with newly diagnosed MM not eligible for ASCT.

cells up close, About page
EAE127
Multiple Myeloma

A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, pomalidomide, and dexamethasone in relapsed/refractory MM patients treated with one line of therapy who are lenalidomide refractory.

cells up close, About page
EAE128
Multiple Myeloma

A Phase 1/2 study of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in naïve transplant ineligible MM patients.

cells up close, About page
MajesTEC-4
Multiple Myeloma

A phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with NDMM as Maintenance Therapy Following ASCT

cells up close, About page
IsKia
Multiple Myeloma

A Phase 3 study of Isatuximab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) vs KRd alone in treatment naïve MM patients eligible for ASCT.

cells up close, About page
EAE 116
Multiple Myeloma

A Phase 2 multi-centre study of isatuximab, bortezomib, cyclophoshamide and dexamethasone, followed by isatuximab-lenalidomide maintenace in treatment naïve MM patients with severe renal impairment.

cells up close, About page
EAE 115
Multiple Myeloma

A Phase 2 multi-centre study of isatuximab in combination with pomalidomide and dexamethasone in 1st relapse lenalidomide and proteasome inhibitor exposed MM patients.